This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bear Stalking Biotech Sector

Amgen reported earnings that were 16 cents ahead of estimates, thanks to strong sales across several drug franchises, including Aranesp, Neulasta, Neupogen and Enbrel. Genentech topped estimates by 4 cents with the help of better-than-expected sales of Avastin and Herceptin. Genzyme also turned in a profit that was 4 cents better than estimates, thanks to gross margin improvements.

Schoenebaum views Amgen's ongoing pipeline positively, pointing to the experimental postmenopausal osteoporosis drug AMG-162 as an important drug in development. Additionally, he sees Genentech reporting solid second-half profits, buoyed by Avastin and Herceptin, despite possible manufacturing constraints.

Although he admits he doesn't love Genzyme, Schoenebaum sees an upside once 2006 arrives -- that's when the Medicare prescription drug program is expected to cover the kidney disease drug Renagel, and the analyst says the coverage isn't fully considered in to the company's sales projections.

Schoenebaum has a peer perform rating on Amgen. Genentech, Genzyme, Idenix (IDIX) and Nabi (NABI) are rated outperform.

Also, the analyst says that among the stocks with peer perform designations, he and his team "see modest potential upside this year" for MedImmune (MEDI).
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
NABI $10.80 0.00%
AMGN $154.49 0.63%
IDIX $24.50 0.20%
AAPL $126.47 0.83%
FB $87.77 2.30%

Markets

DOW 17,740.97 +121.46 0.69%
S&P 500 2,075.81 +12.70 0.62%
NASDAQ 5,019.5620 +32.6950 0.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs